First-line hormone treatment for endometriosis
- Autores: Tikhomirov A.L1
-
Afiliações:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
- Edição: Nº 5 (2021)
- Páginas: 153-157
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/249264
- DOI: https://doi.org/10.18565/aig.202L5.153-156
- ID: 249264
Citar
Texto integral
![Acesso aberto](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_open.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_unlock.png)
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Resumo
The review demonstrates that endometriosis is now considered as a chronic recurrent disease that requires early diagnosis and long-term, often combination treatment. It analyzes the efficacy of drugs used in the treatment of endometriosis and the mechanism of their action. First-line hormone therapy is recognized to be the use of currently available progestogens that can be successfully used in outpatient practice not only for relief of endometriosis-associated painful symptoms, but also for anti-relapse purposes after laparoscopic surgery. Dienogest is a thoroughly studied drug as this approach. The review considers the results of hormone treatment with a progestogen (a dienogest 2 mg tablet) that causes a decidual transformation, as well as antiinflammatory and anti-angiogenic effects in the endometrioid explants, which can yield the favorable results of dienogest therapy in young patients with deep infiltrating endometriosis who have refused surgical treatment. Conclusion. It presents the importance of timely diagnosis of endometriosis and the feasibility of a combined approach to its treatment, including medical (nonsteroidal anti-inflammatory drugs, progestins, hormonal contraceptives, aromatase inhibitors, progesterone receptor modulators) and surgical methods.
Palavras-chave
Texto integral
![Acesso é fechado](https://journals.eco-vector.com/lib/pkp/templates/images/icons/text_lock.png)
Sobre autores
A. Tikhomirov
A.I. Evdokimov Moscow State University of Medicine and Dentistry, Ministry of Health of Russia
Email: padficoff@mail.ru
MD, Professor of the Department of Obstetrics and Gynecology of the Medical Faculty 20/1, Delegatskaya str., Moscow, 127473, Russia
Bibliografia
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. МКБ 10: N80 ГО:КР259/1. Российское общество акушеров-гинекологов; 2020
- Rogers P.A., Adamson G.D., Al-Jefout M., Becker C.M., D'Hooghe T.M., Dunselman G.A. et al. Research priorities for endometriosis. Reprod. Sci. 2017; 24(2): 202-26. https://dx.doi.org/10.1177/1933719116654991.
- Dunselman G.A., Vermeulen N., Becker C., Calhaz-Jorge C., D'Hooghe T., De Bie B. et al. ESHRE guideline: management of women with endometriosis. Hum. Reprod. 2014; 29(3): 400-12. https://dx.doi.org/10.1093/humrep/det457.
- Saraswat L, Ayansina D, Cooper K., Bhattacharya S., Horne A., Bhattacharya S. Impact of endometriosis on risk of further gynaecological surgery and cancer: a national cohort study. BJOG. 2018; 125(1): 64-72. https://dx.doi. org/10.1111/1471-0528.14793.
- Дубровина С.О., Берлим Ю.Д. Медикаментозное лечение боли, связанной с эндометриозом. Акушерство и гинекология. 2019; 2: 34-40. https:// dx.doi.org/10.18565/aig.2019.2.34-40.
- Министерство здравоохранения Российской Федерации. Клинические рекомендации. Эндометриоз. МКБ-10: N80 ГО:КР259. Общество по репродуктивной медицине и хирургии; Российская ассоциация гинекологов-эндоскопистов; Российская ассоциация по эндометриозу; Российская ассоциация эндокринологов; Российское общество акушеров-гинекологов; 2016. Эндометриоз. Клинические рекомендации МЗ РФ, 2016
- Xholli A., FiLip G, Previtera F., Cagnacci A. Modification of endometrioma size during hormone therapy containing dienogest. Gynecol. Endocrinol. 2020; 36(6): 545-9. https://dx.doi.org/10.1080/09513590.2019.1703942.
- Patel B.G., Rudnicki M., Yu J., Shu Y., Taylor R.N. Progesterone resistance in endometriosis: origins, consequences and interventions. Acta Obstet. Gynecol. Scand. 2017; 96(6): 623-32. https://dx.doi.org/10.1111/ aogs.13156.
- Abdou A.M., Ammar I.M.M., Alnemr A.A.A., Abdelrhman A.A. Dienogest Versus Leuprolide Acetate for Recurrent Pelvic Pain Following Laparoscopic Treatment of Endometriosis. J. Obstet. Gynaecol. India. 2018; 68(4): 306-13. https://dx.doi.org/10.1007/s13224-018-1119-3.
- Maiorana A., Incandel D., Parazzini F., Alio W., Mercurio A., Giambanco L., Alio L. Efficacy of dienogest in improving pain in women with endometriosis: a 12-month single-center experience. Arch. Gynecol. Obstet. 2017: 296(3): 42933. https://dx.doi.org/10.1007/s00404-017-4442-5.
- Sugimoto K., Nagata C., Hayashi H., Yanagida S., Okamoto A. Use of dienogest over 53 weeks for the treatment of endometriosis. J. Obstet. Gynaecol. Res. 2015; 41(12): 1921-6. https://dx.doi.org/10.1111/jog.12811.
- Hirata T., Izumi G., Takamura M., Saito A., Nakazawa A., Harada M. et al. Efficacy of dienogest in the treatment of symptomatic adenomyosis: a pilot study. Gynecol. Endocrinol. 2014; 30(10): 726-9. https://dx.doi.org/10.3109/ 09513590.2014.926882.
- Takaesu Y., Nishi H., Kojima J., Sasaki T., Nagamitsu Y., Kato R., Isaka K. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. J. Obstet. Gynaecol. Res. 2016; 42(9): 1152-8. https://dx.doi.org/10.1111/jog.13023.
- Lee S.R., Yi K.W., Song J.Y., Seo S.K., Lee D.Y., Cho S., Kim S.H. Efficacy and safety of long-term use of dienogest in women with ovarian endometrioma. Reprod. Sci. 2017; 25(3): 341-6. https://dx.doi.org/10.1177/1933719117725820.
- Agarwa S., Fraser M.A., Chen I., Singh S.S. Dienogest for the treatment of deep endometriosis: Case report and literature review. J. Obstet. Gynaecol. Res. 2014: 41(2): 309-13. https://dx.doi.org/10.1111/jog.12527.
- Techatraisak K., Hestiantoro A., Ruey S., Banal-Silao M.J., Kim M.R., Seong S.J. et al. Effectiveness of dienogest in improving quality of life in Asian women with endometriosis (ENVISIOeN): interim results from a prospective cohort study under real-life clinical practice. BMC Womens Health. 2019; 19(1): 68. https:// dx.doi.org/10.1186/s12905-019-0758-6.
- Strowitzki T., Faustmann T., Gerlinger C., Schumacher U., Ahlers C., Seitz C. Safety and tolerability of dienogest in endometriosis: pooled analysis from the European clinical study program. Int. J. Womens Health. 2015; 7: 393-401. https://dx.doi.org/10.2147/IJWH.S77202.
Arquivos suplementares
![](/img/style/loading.gif)